News

Arcturus Therapeutics Begins Phase 2 Studies for CF Treatment

Arcturus Therapeutics Begins Phase 2 Studies for CF Treatment

Arcturus Therapeutics Initiates Dosing in Phase 2 Studies

SAN DIEGO -- Arcturus Therapeutics Holdings Inc. (the Company, Arcturus; Nasdaq: ARCT), a pioneer in messenger RNA medicines, is thrilled to announce the initiation of dosing for participants in its Phase 2 multiple ascending dose studies targeting Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency.

Progress in Phase 2 CF Study

In an exciting development for the CF community, the first participants in the Phase 2 clinical trial are set to commence treatment with ARCT-032. The regimen includes daily treatments over a 28-day duration designed to assess the safety and efficacy of this innovative therapeutic approach.

Details of the Study

This study, labeled as NCT06747858, aims to trial the effectiveness of ARCT-032 in individuals with cystic fibrosis, a life-threatening genetic condition. Expectations are high that ARCT-032 will meet the significant medical needs for patients who do not respond to current treatment options.

OTC Deficiency Treatment Study

The research expands further into the realm of metabolic disorders with the commencement of the inaugural dosing for an OTC deficient participant, who will be receiving 0.5 mg/kg of ARCT-810. This individual started their treatment in the United States. The regimen consists of five intravenous infusions spread over a two-month window.

Advancing Innovations

Previously, the company completed a dosing phase in a European placebo-controlled study involving eight participants administered 0.3 mg/kg of ARCT-810. With the expansion of its clinical program in the United States, the research will help ascertain the therapeutic potential of this groundbreaking treatment.

Insights from Leadership

Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, expressed enthusiasm regarding the progress of these Phase 2 studies. He emphasized, "ARCT-032 has the potential to address the significant unmet medical need in the CF community for those who do not qualify for or benefit from available treatment options."

Understanding Cystic Fibrosis

Cystic fibrosis is a genetic disorder that severely impacts respiratory function. It is caused by mutations in the CFTR gene, resulting in the malfunction of the CFTR protein, essential for maintaining the balance of salt and water in tissues. Currently, around 40,000 individuals in the U.S. confront this condition, with over 105,000 living with it globally.

Standard Treatments

Numerous patients with cystic fibrosis benefit from CFTR modulators, but approximately 15% do not due to the absence of functional CFTR proteins or intolerance to existing therapies. Thus, innovative solutions like ARCT-032 are critical in filling this therapeutic gap.

A Closer Look at ARCT-032

ARCT-032 represents a novel medicinal approach, administrating mRNA therapeutically designed to generate functional CFTR in the lungs of patients. With Orphan Medicinal Product Designation from the European Medicines Agency and Orphan Drug Designation from the FDA, it is tailored to restore CFTR function, making strides to mitigate the disease's progression.

Potential Impact

The approach of targeting lung disease, a primary mortality factor for CF patients, carries potential for substantial improvements in quality of life and survival rates, essential as the need for functional CFTR proteins becomes paramount.

Focus on Ornithine Transcarbamylase Deficiency

OTC deficiency is a severe genetic disorder disrupting the body's ability to eliminate ammonia, a toxic waste product. The disease results from mutations in the OTC gene, affecting critical metabolic processes. Current treatment options often involve maintaining strict dietary controls and nitrogen scavenging medications, yet these do not tackle the root causes of the disorder.

ARCT-810's Role

ARCT-810, an investigational mRNA therapy given intravenously, aims to express the normal OTC enzyme within the liver cells of affected individuals. By addressing the root deficiency in OTC enzyme production, it holds the promise of revolutionizing care for OTC deficiency patients.

About Arcturus Therapeutics

Founded in 2013, Arcturus Therapeutics, located in San Diego, California, focuses on advancing mRNA-based medicines and vaccines. Their diverse pipeline demonstrates promise in treating conditions such as cystic fibrosis and OTC deficiency, utilizing their proprietary delivery platforms for optimized therapeutic outcomes.

Looking Ahead

As mRNA technologies continue to evolve, Arcturus’ dedication to pioneering these innovative therapies reinforces its commitment to addressing pressing healthcare needs around the globe. Their endeavor to restore health through cutting-edge science solidifies their role at the forefront of modern medicine.

Frequently Asked Questions

What is the main goal of Arcturus's Phase 2 studies?

The primary goal is to evaluate the safety and effectiveness of ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency.

How many participants are included in these studies?

The studies include multiple ascending dose participants, with specific dosing regimens established for each treatment.

What are ARCT-032 and ARCT-810 targeting?

ARCT-032 targets cystic fibrosis by restoring CFTR protein function, while ARCT-810 focuses on replenishing the OTC enzyme in the liver.

What challenges do cystic fibrosis patients face?

Many patients struggle with inadequate treatment options, with around 15% not benefiting from existing medicines due to their specific genetic variations.

How is Arcturus positioned in the mRNA therapeutic field?

Arcturus is at the forefront, pioneering mRNA technologies with a focus on rare diseases, leveraging their proprietary platforms and extensive patent portfolio.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 121

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 28

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 83

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 30

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 106

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 22

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 81

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 111

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched for SelectQuote, Inc. Shareholders

Updated Category News Views 231

Rosen Law Firm Investigates SelectQuote, Inc. Securities Claims The Rosen Law Firm has recently announced an investigation focusing on SelectQuote, Inc. (NYSE: SLQT) due to potential securities claims that may affect shareholders. The firm is dedicated to upholding investor rights and protecting shareholders from misleading information that might influence stock...

Continue Reading
Indonesia's IDX Composite Index Experiences Minor Decline

Updated Category News Views 239

Well, let’s cut to the chase. Indonesia's stock market is feeling a bit queasy lately. The IDX Composite Index slipped by 0.18%, taking a hit thanks to major sectors like Financials, Infrastructure, and Agriculture showing significant losses. This isn’t just some random shuffle; these sectors often serve as economic bellwethers that reflect broader trends in the...

Continue Reading
Trade Tensions Impact Qualcomm Stock Performance Today

Updated Category News Views 126

Trade Tensions Impact Qualcomm Shares Qualcomm Inc (NASDAQ: QCOM) is experiencing a decline in its share price, attributed to rising trade tensions. Reports indicate that the U.S. government is preparing to implement restrictions on AI chip shipments to certain Southeast Asian countries, primarily Malaysia and Thailand, due to ongoing concerns regarding China. New Export...

Continue Reading
Historic $100 Million Donation to Improve Pediatric Mental Health

Updated Category News Views 184

Transforming Pediatric Behavioral Health BOSTON — A groundbreaking gift of $100 million from Rob and Karen Hale has been announced by Boston Children's Hospital. This donation marks the largest in the hospital's storied history and is set to revolutionize pediatric behavioral health care. The Hale family's incredible generosity is aimed at reimagining how mental and...

Continue Reading
Mark Carney Takes Charge: Canada's Bold Steps to Trade Victory

Updated Category News Views 414

Mark Carney: Canada's New Prime Minister Mark Carney has emerged victorious in the leadership race of the Liberal Party, succeeding Justin Trudeau as Canada’s prime minister. With a commanding win, he pledged to confront U.S. President Donald Trump head-on, especially regarding increasing trade tensions. A Strong Start in Leadership In a remarkable demonstration of...

Continue Reading